Cas:3648-18-8 Bis(lauroyloxy)dioctyltin manufacturer & supplier

Chemical Name:Bis(lauroyloxy)dioctyltin

CAS.NO:3648-18-8

Synonyms:Bis(lauroyloxy)dioctylstannane;Di-n-octyltin dilaurate;Stannane,dioctyldi(lauroyloxy);dioctyl dilaurate;Tin,dioctyl-,dilaurate;Stannane,didodecanoyloxydioctyl;dioctyl-dilauroyloxytin;Bis(Lauroyloxy)Dioctyltin;Stannane,dioctyldidodecanoyloxy;1,2-bis(lauroyloxy)dioctylstannane;Stannane,bis(lauroyloxy)dioctyl;Dioctyltin dilaurate

Molecular Formula:C₄₀H₈₀O₄Sn

Molecular Weight:743.76200

HS Code:2915900090

Physical and Chemical Properties:

Melting point:17-18ºC

Boiling point:N/A

Density:0.998 g/cm3

Index of Refraction:

PSA:52.60000

Exact Mass:744.50800

LogP:14.07780

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Bis(lauroyloxy)dioctylstannane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dioctyltin dilaurate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Bis(Lauroyloxy)Dioctyltin Use and application,Stannane,dioctyldi(lauroyloxy) technical grade,usp/ep/jp grade.

Related News: EMA’s human medicines committee (CHMP) has endorsed findings of a review which concluded that there is no evidence Zynteglo causes a blood cancer known as acute myeloid leukaemia (AML). Benz[5,6]indeno[1,2,3-cd]perylo[3′,4′:5,6,7]-s-indaceno[1,2,3-lm]perylene, 5,15-diphenyl- manufacturers The Company’s Family 1 includes patent-pending compounds comprising two patent applications with priority dates of February 2020. Oxidase, cytochrome (Patiriella gunnii strain MOL130 country Australiamitochondria-encoded gene COI subunit I N-terminal fragment) suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. Benzenecarbothioic acid, 3,5-dimethyl-, S-2-pyridinyl ester vendor & factory.